Jeffrey R Curtis

• MD MS MPH
• Professor at University of Alabama at Birmingham

To evaluate the accuracy, reliability, and usability of Bend Ease, a novel smartphone-based digital health technology (DHT), which objectively self-measures spinal range of motion (SRoM) and remotely assesses morning stiffness. This phase 1 study involved healthy volunteers (HV) and patients with axial spondyloarthritis (axSpA). Participants used B...

Background: Potential associations between targeted therapies and a new cancer in patients with inflammatory arthritis (IA) and a previous malignancy are a frequent concern in daily rheumatology practice. Objectives: To develop points to consider (PTC) to assist rheumatologists when initiating a targeted therapy in the context of a previous mali...

Objectives Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS). Method Pooled data from Phase 2 (NCT01786668; 04/2013–03/2015)/Phase 3 (NCT03502616; 06/2018–08/2020) RCTs in AS patients were analyzed (3 overlapping cohorts): 16-week placebo-controlled (tofaciti...

Purpose The Excellence Network in RheumatoloGY (ENRGY) was founded in 2021 and encompasses data from more than 700 private practice rheumatology providers throughout the United States, forming a practice‐based research network (PBRN). Methods Electronic health record (EHR) data from participating practices are aggregated, including structured data...

Objective We determined if metabolic syndrome, its components, and adipokines (adiponectin, leptin, and fibroblast growth factor‐21) were associated with response to advanced therapies among patients with rheumatoid arthritis (RA). Methods This study included participants with RA initiating either tumor necrosis factor inhibitor (TNFi) or non‐TNFi...

BACKGROUND Patients with immune-mediated inflammatory disease (IMID), including autoimmunity, fared significantly worse than the general population during the COVID-19 pandemic both in terms of infection outcomes and levels of life disruption. Despite this, COVID-19 vaccine uptake has not been universal. The absence of IMID patients from clinical t...

Background It is unknown if steroid use could interfere with the benefits of immune checkpoint inhibitors (ICI) as cancer therapies in Rheumatoid Arthritis patients (RA). Additionally, it is unknown what a ‘safe’ daily dosage of steroids would be in ICI-treated RA patients. Therefore, we examined the association between steroid use after ICI initia...

Background Patients with autoimmune diseases, such as rheumatoid arthritis (RA), were excluded from clinical trials for immune checkpoint inhibitors (ICI). This exclusion has yielded uncertainty in the comparability of the overall survival benefits of ICI treatment in non-small cell lung cancer (NSCLC) patients with RA. The aim of this study was to...

Objective Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme, that has been implicated as a biomarker of cardiovascular risk in patients with rheumatoid arthritis (RA). We aimed to investigate how different biologic therapies affect levels of PON1 and oxylipins. Methods 1213 adult patients with RA in the Comparative Effecti...

Objective This study aimed to validate claims-based algorithms for identifying SLE and lupus nephritis (LN) in Medicare data, enhancing the use of the Lupus Index for geospatial research on SLE prevalence and outcomes. Methods We retrospectively evaluated the performance of rule-based algorithms using the International Classification of Diseases,...

Purpose: Few studies have reported the agreement between medication information derived from ambulatory EHR data compared to administrative claims for high-cost specialty drugs. We used data from a national EHR-enabled registry, the Rheumatology Informatics System for Effectiveness (RISE), with linked Medicare claims in a population of patients wi...

Epidural steroid injections (ESIs) are a common and often effective treatment for radicular back pain. While oral glucocorticoids increase fracture incidence, little is known regarding fracture risk after ESI. This study investigated the incidence of fractures among individuals who received ESI and those who did not. We hypothesized that ESI exposu...

The Veterans Health Administration (VHA) listed the infliximab (IFX) biosimilar, IFX-dyyb (Inflectra), on the Veterans Affairs National Formulary (VANF) in May 2017. In September 2018, biosimilar IFX-abda (Renflexis) became the VANF IFX product. The recommended formulary changes from one IFX biosimilar to another provided a unique opportunity to st...

Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs) with guselkumab in patients with active psoriatic arthritis (PsA). Post hoc analyses evaluated 1120 patients with PsA rec...

Objectives To assess the impact of baseline RF level on drug concentrations and efficacy of certolizumab pegol [CZP; TNF inhibitor (TNFi) without a crystallizable fragment (Fc)] and adalimumab (ADA; Fc-containing TNFi) in patients with RA. Methods The phase 4 EXXELERATE study (NCT01500278) was a 104-week, randomized, single-blind (double-blind unt...

Objective Many guidelines recommend limiting glucocorticoids in patients with rheumatoid arthritis (RA), but 40% of patients remain on glucocorticoids long term. We evaluated the cardiovascular risk of long‐term glucocorticoid prescription by studying patients on stable disease‐modifying antirheumatic drugs (DMARDs). Methods Using two claims datab...

Objective To assess the association of trimethoprim sulfamethoxazole (TMP-SMX) prophylaxis with serious infections in rituximab-treated patients with granulomatosis with polyangiitis (GPA). Methods This retrospective cohort study included adults with GPA (2011–2020) within the United States Merative™ Marketscan® Research Databases with ≥6 months’...

Objective Quality of care (QoC) delivery in rheumatoid arthritis (RA) continues to suffer from various challenges (eg, delay in diagnosis and referral) that can lead to poor patient outcomes. This study aimed to identify good practice interventions that address these challenges in RA care in North America. Methods The study was conducted in three...

Objective The objective of this study was to ascertain pegloticase persistence and adverse events associated with concomitant immunomodulatory drug treatment in patients with gout. Methods We conducted a retrospective analysis of patients with gout using the American College of Rheumatology's Rheumatology Informatics System for Effectiveness regis...

Objectives Immune checkpoint inhibitor (ICI) associated inflammatory arthritis (ICI-IA) occurs in 4–6% of ICI-treated patients based on one observational study. We identified cases of ICI-IA using administrative claims to study its incidence and characteristics at the population level. Methods We used the Medicare 5% sample to identify patients in...

Background Given an increased risk of COVID-19 in patients with autoimmune conditions, we must better understand the immunogenicity and safety of SARS-CoV-2 vaccines in people living with rheumatic disease. We conducted the Covid VaccinE Response (COVER) trial, a multicenter, randomized controlled trial to assess the response to the SARS-CoV-2 boos...

Background Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from randomized trials evaluating fracture outcomes is lacking. Objectives This retrospective cohort study evaluated the comparative effectiveness of Dmab versus ZA in redu...

Background During the COVID-19 pandemic, telemedicine was widely adopted as an approach to care for people with rheumatic diseases. Data on whether telemedicine is as good as in-person care in terms of patient satisfaction and effectiveness of care in rheumatology is limited. Objectives We aimed to determine whether telemedicine visits were noninf...

Background In patients (pts) with rheumatoid arthritis (RA), high rheumatoid factor (RF) levels are a poor prognostic factor and associated with higher disease activity, risk of progression, and decreased response to monoclonal antibodies (mAbs) targeting tumour necrosis factor (TNF).1,2,3 Recent data suggest pts with RA and high RF levels have bet...

Background Recruiting patients for research is one of the most challenging aspects of a study. Researchers may employ a plethora of methods to recruit patients, including physician referrals, flyers, emails, patient portal messages, social media announcements and cold calls. Objectives The objective of this study was to assess the impact of recrui...

Background Treat-to-target (T2T) is the recommended disease-management strategy for rheumatoid arthritis (RA). T2T relies on shared decision-making that should include use of patient-reported outcomes (PROs) that may be captured electronically (ePROs). PROs/ePROs complement clinical measures of disease activity and can help clinicians understand sy...

Background Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated efficacy and safety across several rheumatic diseases, including RA, PsA, AS (also called r-axSpA), and nr-axSpA. Safety observed with JAK inhibition to date has highlighted the need to further characterize the long-term safety profile of individual JAK inhibitors across diverse...

Background Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) are new care delivery options by which patients can provide data to their provider via a biosensor device and/or smartphone app in an insurance reimbursable fashion. Objectives Assess patients’ willingness to engage in RPM/RTM and persistence with the program ov...

Background Infection is a major cause of mortality within the first year of induction therapy in patients with ANCA-associated vasculitis (AAV). A recent EULAR AAV guideline recommends the prophylactic use of trimethoprim-sulfamethoxazole (TMP-SMX) against Pneumocystis jirovecii pneumonia (PJP) and other infections. However, while a limited number...

Background Polymyalgia Rheumatica (PMR) is a common inflammatory rheumatic condition in people aged ≥50 years with incidence peaking at 70–80 years. PMR is primarily treated with glucocorticoids (GC) with guideline recommended treatment duration of 36–48 weeks without a flare or 40–52 weeks with a single flare.[1] However, it is estimated that 77%,...

Background Although clinical trials have shown that transitioning from bisphosphonates (BP) to denosumab (Dmab) increases bone mineral density at key skeletal sites more than remaining on BP, evidence from head-to-head studies evaluating fracture outcomes is lacking. Objectives This retrospective observational study compared the effectiveness of D...

Background Treatment of polymyalgia rheumatica (PMR), a common inflammatory rheumatic disease in older adults, is hindered by a paucity of glucocorticoid (GC)-sparing therapies with proven efficacy. A retrospective study showed treatment with IL-6 receptor inhibitors (IL-6Ri) vs. conventional synthetic immunomodulatory drugs (csIM [methotrexate, le...

Background Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) have an increasing array of treatment options available, and new blood-based diagnostic tests to predict future treatment response are commercially available or are in development. Moreover, certain medications are restricted to patien...

Background Glucocorticoids (GCs) are the mainstay of treatment for polymyalgia rheumatica (PMR). However, a substantial proportion of patients treated with GC may not achieve GC-free remission or may not be able to taper GC without experiencing flares.[1] It is estimated that almost 50% of patients experience a disease flare upon GC taper or discon...

Background The adjuvanted recombinant glycoprotein E (gE) herpes zoster vaccine (RZV) received expanded approval for use in 2021 for adults receiving immunosuppression. Despite approval, little clinical or immunogenicity data exist of RZV in rheumatoid arthritis (RA) patients who are at high risk of herpes zoster (HZ). Further, it is unclear if bio...

Background There is varied distribution of psoriasis and psoriatic arthritis across the world, with greater prevalence in high income countries, including the US, but with more severe functional impairment and morbidity in low-income countries. Despite recommendations for escalating treatment to achieve low disease activity, select cohorts of PsA p...

Although clinical trials have shown that denosumab significantly increases bone mineral density at key skeletal sites more than oral bisphosphonates, evidence is lacking from head-to-head randomized trials evaluating fracture outcomes. This retrospective cohort study uses administrative claims data from Medicare fee-for service beneficiaries to eva...

Introduction To investigate health disparities in SLE, geographic variables must be considered in predicting outcomes of patients with systemic lupus erythematosus (SLE). The Lupus Index is a GIS-based data set was developed by the Lupus Research Alliance in collaboration with the Center for Medicare Services and the National Minority Quality Forum...

Objective We sought to identify (a) what types of information US adults with rheumatic and musculoskeletal diseases (RMD) perceive as most important to know about their disease, and (b) what functions they would use in an RMD-specific smartphone app. Methods Nominal groups with RMD patients were conducted via online tools to generate a list of nee...

Objectives To examine determinants of tofacitinib discontinuation due to voluntary (i.e. patient-driven) or involuntary reasons (i.e. protocol mandated) in long-term extension (LTE) studies of patients with RA to inform clinical practice, clinical study execution and data capture. Methods This post hoc analysis used pooled data from patients recei...

Background A multi-biomarker disease activity (MBDA)-based cardiovascular disease (CVD) risk score was developed and internally validated in a Medicare cohort to predict 3-year risk for myocardial infarction (MI), stroke or CVD death in patients with rheumatoid arthritis (RA). It combines the MBDA score, leptin, MMP-3, TNF-R1, age and four clinical...

Background/Aims In patients with rheumatoid arthritis (RA), high rheumatoid factor (RF) titres are considered a poor prognostic factor and are associated with higher disease activity, risk of radiographic progression and decreased response to TNF inhibitors (TNFis). Recent data suggests that patients with RA and high RF titre may achieve and mainta...

Background/Purpose Little is known about long-term clinical outcomes or urate-lowering (ULT) therapy use following pegloticase discontinuation. We examined ULT use, serum urate (SU), inflammatory biomarkers, and renal function following pegloticase discontinuation. Methods We conducted a retrospective analysis of gout patients who discontinued peg...

Objective The aim of this study was to describe the adult rheumatology workforce in the United States, assess change in rheumatology providers over time, and identify variation in rheumatology practice characteristics. Methods Using national Medicare claims data from 2006 to 2020, clinically active rheumatology physicians and advanced practice pro...

Objective The study objective was to update a method to identify comorbid conditions using only medication information in circumstances in which diagnosis codes may be undercaptured, such as in single‐specialty electronic health records (EHRs), and to compare the distribution of comorbidities across Rx‐Risk versus other traditional comorbidity indi...

Objective We performed a scoping review of the relevant literature on home‐based telehealth in rheumatology to understand its appropriate application in rheumatology practice. Methods We searched the Cochrane Library, PubMed, Web of Science, and scientific meeting abstracts to identify articles that specifically addressed telehealth suitability, b...

To evaluate the effect of guselkumab on work productivity and nonwork daily activity impairment and general health status through 2 years in patients who were biologic-naïve with active psoriatic arthritis (PsA) in the phase 3 DISCOVER-2 clinical trial. Adult patients with PsA were randomized to subcutaneous injections of guselkumab 100 mg every 4...

Background Digital health studies using electronic patient reported outcomes (ePROs), wearables, and clinical data to provide a more comprehensive picture of patient health. Methods Newly initiated patients on upadacitinib or adalimumab for RA will be recruited from community settings in the Excellence NEtwork in RheumatoloGY (ENRGY) practice-base...

Objective The objective of this study was to determine the proportion of new medication prescriptions observed in electronic health records (EHR) that represent true incident medication use, accounting for undocumented previous prescriptions (prevalent medication use) and failure to initiate treatment (primary nonadherence) with linked administrati...

To construct a model of the antibody response to COVID-19 vaccination in patients with rheumatoid arthritis (RA), and to identify clinical factors affecting the antibody response. A total of 779 serum samples were obtained from 550 COVID-19-naïve RA patients who were vaccinated against COVID-19. Antibody titers for the receptor binding domain (anti...

Purpose To determine if body mass index (BMI) and adipokine levels identify rheumatoid arthritis (RA) patients most likely to benefit from initiation of tumour necrosis factor inhibitors (TNFi) after methotrexate inadequate response. Methods This is a secondary analysis of the Rheumatoid Arthritis Comparison of Active Treatments (RACAT) trial and...

Purpose To develop a natural language processing (NLP) tool to extract forced vital capacity (FVC) values from electronic health record (EHR) notes in patients with rheumatoid arthritis‐interstitial lung disease (RA‐ILD). Methods We selected RA‐ILD patients ( n = 7485) in the Veterans Health Administration (VA) between 2000 and 2020 using validate...

Objective The goal of this study was to ascertain COVID‐19 vaccine uptake, reasons for hesitancy, and self‐reported flare in a large rheumatology practice‐based network. Methods A tablet‐based survey was deployed by 108 rheumatology practices from December 2021 to December 2022. Patients were asked about COVID‐19 vaccine status and why they might...

To assess cigarette smoking’s effects on efficacy of the preferential Janus kinase (JAK) 1 inhibitor filgotinib and drug persistence in patients with rheumatoid arthritis (RA). Efficacy in non-smokers, former smokers, and current smokers from phase 3 filgotinib trials was analyzed, including patients with inadequate response (IR) to methotrexate (M...

We appreciate the comments shared by Wang and colleagues. ¹ Here we provide responses to the key comments that were raised and highlight relevant aspects in our original publication ² and from our research. The first point highlighted by Wang et al was regarding the limitations associated with using diagnosis codes for the identification of rheumat...

This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) treated with upadacitinib (UPA) or active comparators. This integrated safety analysis includes data from 11 phase 3 UPA trials across RA (6 trials), Ps...

Objective An interactive tool identifying treatment attributes important to patients can enhance shared decision‐making (SDM) in rheumatoid arthritis (RA). A formative survey was conducted to identify the most important treatment attributes from patients’ perspective, which can be used to develop an interactive SDM tool. Methods The survey was per...

Clinical guidelines offer little guidance for treatment selection following inadequate response to conventional synthetic disease-modifying antirheumatic drug (csDMARD) in rheumatoid arthritis (RA). A molecular signature response classifier (MSRC) was validated to predict tumor necrosis factor inhibitor (TNFi) inadequate response. The decision impa...

Objectives To provide an integrated analysis of major adverse cardiovascular events (MACEs) and events of venous thromboembolism (VTE) and associated risk factors across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) phase 2b/3 upadacitinib clinical programmes. Methods Data were analysed and summarised from c...

Objective This study describes the demographics, comorbidities, and treatment patterns in a national cohort of patients with polymyalgia rheumatica (PMR) who received care from rheumatology providers. Methods Patients with PMR were identified in the American College of Rheumatology Rheumatology Informatics System for Effectiveness registry from 20...

Objective Uptake of treat-to-target (TTT) strategies for rheumatoid arthritis (RA) management is low. Our objective was to understand the heterogeneity in patients’ conceptualisation of RA treatment to inform interventions improving TTT uptake. Design Eligible participants recruited from an online research registry rated 56 items (on 5-point scale...

Objective To evaluate the relative prevalence of 8 rheumatic and musculoskeletal diseases (RMDs) across racial/ethnic groups within the Patient-Centered Research Network (PCORnet). Methods Electronic health records from participating PCORnet institutions and systems from January 1, 2013 to December 31, 2018 were used to identify adult patients wit...

Background: Antibiotic prophylaxis is recommended during ANCA-associated vasculitis (AAV) induction. We aimed to describe the frequency, persistence, and factors associated with trimethoprim-sulfamethoxazole (TMP-SMX) use in an adult population sample with granulomatosis with polyangiitis (GPA) treated with rituximab (RTX). Methods: We identifie...

Objective To determine whether unique multimorbidity patterns are associated with long‐term rheumatoid arthritis (RA) disease severity. Methods We conducted a cohort study within the Veterans Affairs Rheumatoid Arthritis registry. We applied previously derived multimorbidity patterns based on the presence of diagnostic codes for relevant condition...

Objective: To examine how patients with rheumatoid arthritis (RA) perceive RA-related lab testing and the potential utility of a blood test to predict treatment response to a new RA medication. Methods: ArthritisPower members with RA were invited to participate in a cross-sectional survey on reasons for laboratory testing, plus a choice-based co...

Purpose: To assess accuracy of administrative claims prescription fill-based estimates of glucocorticoid use and dose, and approximate bias from glucocorticoid exposure misclassification. Methods: We identified adults with rheumatoid arthritis with linked Medicare and CorEvitas registry data. An algorithm identifying glucocorticoid use and avera...

Introduction: Clinical trial findings may not be generalizable to routine practice. This study evaluated sarilumab effectiveness in patients with rheumatoid arthritis (RA) and tested the real-world applicability of a response prediction rule, derived from trial data using machine learning (based on C-reactive protein [CRP] > 12.3 mg/l and seroposi...

Purpose: Inpatient mortality is an important variable in epidemiology studies using claims data. In 2016, MarketScan data began obscuring specific hospital discharge status types for patient privacy, including inpatient deaths, by setting the values to missing. We used a machine learning approach to correctly identify hospitalizations that resulte...

Objective Increased risk of serious adverse events (AEs) was reported for tofacitinib relative to tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis (RA) aged ≥50 years enriched for cardiovascular (CV) risk (ORAL Surveillance). We assessed post hoc the potential risk of upadacitinib in a similar RA population. Methods P...

Objectives: To determine whether an expanded antigen-specific anti-citrullinated protein antibody (ACPA) profile predicts changes in disease activity in patients with rheumatoid arthritis (RA) initiating biologics. Methods: The study included participants from a prospective, non-randomized, observational RA cohort. For this sub-study, treatment...

Objective: To estimate the incremental healthcare resource utilization (HRU) and cost burden posed by herpes zoster (HZ) in adult patients with rheumatoid arthritis (RA) in the United States. Methods: A retrospective cohort study was conducted using an administrative claims database containing commercial and Medicare Advantage with Part D data,...

Objective: The study objective was to prioritize topics for future patient-centered research to increase uptake of common vaccines, such as for pneumococcal pneumonia, influenza, herpes zoster, human papillomavirus, and severe acute respiratory syndrome coronavirus 2, among adults living with autoimmune conditions. Methods: A steering committee...

It is often difficult to obtain valid estimates of comparative treatment effectiveness and safety owing to differences across patient populations taking different medications in the real world. One approach for assessing comparability between treatment groups in effectiveness studies is to use negative control outcomes (NCOs). NCOs share similar so...

Objective: Some patients with rheumatoid arthritis (RA) who persist in remission may decide to stop their therapy. We evaluated baseline characteristics associated with remaining in remission or low disease activity (LDA) following medication withdrawal. Methods: SEAM-RA was a phase 3, multicenter, randomized withdrawal, double-blind, controlled...

Purpose: We assessed the suitability of pooled electronic health record (EHR) data from Clinical Research Networks (CRNs) of the Patient-Centered Outcomes Research Network to conduct studies of the association between tumor necrosis factor inhibitors (TNFi) and infections. Methods: EHR data from patients with one of seven autoimmune diseases wer...

Objectives: Algorithms have been developed to identify rheumatoid arthritis-interstitial lung disease (RA-ILD) in administrative data with positive predictive values (PPVs) between 70 and 80%. We hypothesized that including ILD-related terms identified within chest computed tomography (CT) reports through text mining would improve the PPV of these...

Background Biologic therapies are often prescribed for patients with rheumatoid arthritis (RA) who have inadequate responses to or are intolerant of methotrexate (MTX) and patients with poor prognostic indicators. This post hoc analysis evaluated effectiveness and safety of intravenous golimumab + MTX vs golimumab without MTX in RA patients. Metho...

Objective: The aim of this study was to assess the change in disease activity associated with switching from 1 biologic/targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) to another in patients with rheumatoid arthritis who did not achieve low disease activity (LDA) after 6 to 12 months of their initial treatment. Methods: This...

Background The purpose of this analysis was to assess the frequency of inadequate response over 1 year from advanced therapy initiation among patients with Crohn’s disease (CD) or ulcerative colitis (UC) in the United States using a claims-based algorithm. Factors associated with inadequate response were also analyzed. Methods This study utilized...

Objectives The association between disease activity and infection risk among patients with rheumatoid arthritis (RA) is not clear, and it is challenging to determine because of confounding due to the effects of RA treatments and comorbidities. Methods Using patients with RA in the CorEvitas registry with Medicare coverage in 2006–2019, we identifi...

Objective: The aim of this study was to assess the effect of switching from adalimumab to sarilumab monotherapy in partial responders with rheumatoid arthritis from the MONARCH randomized trial and its open-label extension (OLE). Methods: Partial response was defined as improvement in Clinical Disease Activity Index (CDAI) of 12 or 6 units (base...

Introduction: To assess changes in the Patient-Reported Outcomes Measurement Information System (PROMIS®) outcomes related to social, mental, and physical well-being after approximately 1 year of intravenous (IV) golimumab or infliximab treatment in patients with rheumatoid arthritis (RA) using real-world evidence from AWARE. Methods: AWARE was...

Objective: Our objective was to evaluate the factors associated with regional variation of rheumatoid arthritis (RA) disease burden in the US. Methods: In a retrospective cohort analysis of Rheumatology Informatics System for Effectiveness (RISE) registry data, seropositivity, RA disease activity (Clinical Disease Activity Index [CDAI], Routine...

Abstract Introduction The efficacy of sarilumab and upadacitinib, in combination with disease-modifying antirheumatic drugs (DMARDs), was demonstrated in phase 3 clinical trials of patients with rheumatoid arthritis (RA) refractive to previous biologic DMARDs. In the absence of head-to-head clinical trials, the matching-adjusted indirect comparison...

Objective To provide evidence‐based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases (RMDs). Methods This guideline follows American College of Rheumatology (ACR) policy guiding management of conflicts of interest and disclosures and the ACR guideline development process, which includes...

Objective To provide evidence‐based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases (RMDs). Methods This guideline follows American College of Rheumatology (ACR) policy guiding management of conflicts of interest and disclosures and the ACR guideline development process, which includes...

BACKGROUND Digital health studies using electronic patient reported outcomes (ePROs) and wearables bring new challenges, including activation of participants to consistently provide trial data. OBJECTIVE To characterize engagement, protocol adherence, and data completeness among participants with rheumatoid arthritis (RA) enrolled in the Digital T...